From:	@sanofi.com>			
Sent:	04 September 2020 13:10			
Ta:	(SG-RECOVER)			
Cc:	(SJ); (SJ);			
	@gsk.com; @gsk.com;			
Subject:	RE: EU APA: Proposed draft of for your review			
Attachments:	APARedlineSP_GSK_04092020.docx			
Dean				
Thank you for email.				
As discussed yesterday, please find	attached our last version (subject to proof reading/formatting and			
adjustments and discussions of the	e still open points).			
This attached version includes;				
(1) The modifications we agree upon during our last calls				
(2) GSK and Sanofi Pasteur suggested changes (track changes) further to our yesterday discussions				
Looking forward to get your feedback on the working draft clause sent yesterday after our call and to our joint review Monday morning.				
Best regards				
on behalf of GSK and	Sanofi Pasteur teams			
De: @ec.euro	pa.eu @ec.europa.eu>			
Envoyé : jeudi 3 septembre 2020 1				
	<u>@sanofi.com</u> >			
Cc: @ec.europa				
@sanofi.com>;	@gsk.com @gsk.com			
	oni.com>			
Objet : [EXTERNAL] RE; EU APA; Proposed draft of for your review				
EXTERNAL: Real sender is @ec.europa.eu				
The second secon				
Dear				
Also thanks for the constructive discussions from our side.				
Also thanks for the constructive discussions from our side.				
We will have to check the draft wit you on this by cob tomorrow.	th our We will probably only be able to come back to			
However, why don't you already send the remaining text to us by the envisaged time tomorrow?				
Best regards,				

From:	@sar	nafi.cam>	
Sent: Thur	sday, September 3, 2020 7:16 P	M	
Ta:	(COMP) <	@ec.europa.eu>	
Cc:	(21)	@ec.europa.eu>;	(LZ)
	ec.europa.eu>;	@sa	nofi.com>;
@gsk.com>;		@gsk.cam>;	
	@sanofi.com>		
Subject: El	J APA: Proposed draft of f	ar yaur review	

Dear

As agreed, please find attached the proposed working draft version of article and Our objective is you to have our final complete working draft before tomorrow 2pm so that, as the case may be, the Commission has it in hands for its Steer Co.

We are looking forward for your prompt return on the article hereto (do you have any timelines?)

Thank you again for our constructive discussion today.

Best regards

on behalf of SP and GSK teams